Compare Entegris Inc (ENTG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.

The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.